Última actualización 2 de julio de 2026
Key finding
No significant difference was observed between the two groups in terms of HbA1c (p= 0.263).
This study investigated the effects of vitamin D supplementation on glycemic control in newly diagnosed type 2 diabetes patients. No significant differences were found between the vitamin D group and the standard anti-diabetic drugs group.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study investigated the effects of vitamin D supplementation on glycemic control in newly diagnosed type 2 diabetes patients. No significant differences were found between the vitamin D group and the standard anti-diabetic drugs group.
Understanding the role of vitamin D in diabetes management is crucial, especially as many patients seek complementary therapies. This study's findings suggest that vitamin D supplementation alone may not be effective in improving glycemic control in newly diagnosed type 2 diabetes patients, which can guide clinicians in treatment planning and patient education.
Limited sample size may affect generalizability Short duration of the study may not capture long-term effects Lack of diverse population representation
Published in
Publication details and source links for this paper.
Alexander M, John RA, Kuldeep K, et al. Vitamin D Supplementation and Glycemic Control in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial. Cureus. 2024;16(9):e70224. doi:10.7759/cureus.70224
No significant difference in HbA1c levels (p=0.263)
No significant change in fasting blood sugar levels (p=0.734)
No significant change in insulin resistance levels (p=0.899)
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Standard anti-diabetic drugs only, Vitamin D supplementation and Fasting blood sugar (FBS), Fasting insulin levels, Glucose iAUC (OGTT), and 2 more.
This study contributes evidence to
Primary intervention
Standard anti-diabetic drugs only
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
5
Related topics
10
Evidence pairs
681
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Seguir evidencia
Relación de evidencia
Seguir evidencia
Core evidence
The primary outcomes reported in this study.
Standard anti-diabetic drugs only → Fasting blood sugar (FBS)
Standard anti-diabetic drugs only → Fasting blood sugar (FBS)
Standard anti-diabetic drugs only → Fasting insulin levels
Standard anti-diabetic drugs only → Fasting insulin levels
Standard anti-diabetic drugs only → Glucose iAUC (OGTT)
Standard anti-diabetic drugs only → Glucose iAUC (OGTT)
Standard anti-diabetic drugs only → Insulin resistance
Standard anti-diabetic drugs only → Insulin resistance
Vitamin D supplementation → Fasting blood sugar (FBS)
Vitamin D supplementation → Fasting blood sugar (FBS)
Vitamin D supplementation → Fasting insulin levels
Vitamin D supplementation → Fasting insulin levels
Vitamin D supplementation → Glucose iAUC (OGTT)
Vitamin D supplementation → Glucose iAUC (OGTT)
Vitamin D supplementation → Insulin resistance
Vitamin D supplementation → Insulin resistance
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Vitamin D supplementation and HbA1c, Vitamin D supplementation and Insulin Resistance.
This study contributes to the evidence on the following intervention-outcome relationships.
Supplements
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Vitamin D supplementation
Contributes to Vitamin D supplementation evidence base.
All studies measuring Insulin Resistance
Measures Insulin Resistance as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
5 results
4 results
5 results
5 results
4 results
Generated from the study's connected evidence using Evidence Intelligence™.
Alpha-glucosidase inhibitors may improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Current evidence does not show a clear benefit of Alpha-glucosidase inhibitors for Insulin Resistance.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting insulin levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Insulin resistance
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Alpha-glucosidase inhibitors for Fasting Glucose.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Alpha-glucosidase inhibitors for HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.